rexlemestrocel-l — Topline data
mid-CY2027
Top-line results are expected in mid-CY2027 after the last treated patient has completed 12 months follow-up.Source filing
MESO biotech catalysts & pipeline
MESOBLAST LTD · Data as of 2026-09-08
Upcoming catalysts
rexlemestrocel-l — NDA/BLA submission
Q3 CY2027
A positive readout will be used in support of an expected regulatory filing in Q3 CY2027 for United States Food and Drug Administration (FDA) approval.Source filing